Evaluation of Lenalidomide (REVLIMID) in Cutaneous LE: A Prospective, Non Controlled, Open Label Pilot Study to Evaluate the Off-Label Use of the FDA-Approved Drug Lenalidomide (REVLIMID) in Patients With Cutaneous Lupus Erythematosus

Trial Profile

Evaluation of Lenalidomide (REVLIMID) in Cutaneous LE: A Prospective, Non Controlled, Open Label Pilot Study to Evaluate the Off-Label Use of the FDA-Approved Drug Lenalidomide (REVLIMID) in Patients With Cutaneous Lupus Erythematosus

Completed
Phase of Trial: Phase II

Latest Information Update: 18 Feb 2011

At a glance

  • Drugs Lenalidomide (Primary)
  • Indications Cutaneous lupus erythematosus
  • Focus Therapeutic Use
  • Most Recent Events

    • 18 Feb 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 18 Feb 2011 Actual end date (Oct 2009) added as reported by ClinicalTrials.gov.
    • 25 Oct 2009 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top